Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

KYMR vs INBX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

KYMR Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 5–2 Matrix Metrics)

KYMR Overall Winner 6-Pillar Tally: KYMR 4 – 1 INBX (1 Tie) Matrix Metrics: KYMR 5 – 2 INBX

As of Nov 16, 2026, Kymera Therapeutics, Inc. (KYMR) is the stronger overall head-to-head candidate over Inhibrx Biosciences, Inc. (INBX) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). KYMR carries a Unified Composite Score of 47.1/100 (HOLD) at $124.91 (N/M Forward P/E, -396.0% operating margin), whereas INBX carries 51.4/100 (HOLD) at $77.65 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While INBX currently prints a higher short-term Unified Composite Score (51.4/100 HOLD vs. KYMR 47.1/100 HOLD), KYMR captures the overall institutional head-to-head verdict (5–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-396.0% vs. 0.0% operating margin) and revenue trajectory (+466.4% vs. -100.0% YoY).
  • Technical & Structure Timing Caution: KYMR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.7); meanwhile INBX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About KYMR vs INBX
KYMR NASDAQ Head-to-Head Winner
Kymera Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$124.91
-2.09% 1D
Market Cap $10.9B
TTM Revenue $102M
Forward P/E N/M
Beta / 30D Vol 1.04β · 54% Vol
Unified Composite Score
47.1 / 100 HOLD
Tech 36.0 Fund 50.0 Flow 67.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.0% over 20 days), RSI 52
RSI-14: 51.7 · SMA20: $124.62 · SMA50: $117.28
INBX NASDAQ
Inhibrx Biosciences, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$77.65
-6.78% 1D
Market Cap $1.3B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.53β · 120% Vol
Unified Composite Score
51.4 / 100 HOLD
Tech 48.0 Fund 55.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.0%), weak momentum, RSI 41
RSI-14: 40.6 · SMA20: $85.65 · SMA50: $94.39

6-Pillar Scorecard Institutional Category Breakdown (KYMR 4 – 1 INBX)

Columns: Metric · KYMR · INBX
1. Valuation Multiples KYMR
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 103.3x N/M
2. Growth & Scale KYMR
Revenue Growth (YoY) +466.4% -100.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $102M N/A
Market Cap $10.9B $1.3B
3. Profitability & Quality INBX
Gross Margin N/A N/A
Operating Margin -396.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -27.3% -1773.6%
4. Balance Sheet & Cash Flow KYMR
Cash Generation (TTM) -$289M -$132M
Cash Flow Margin N/A N/A
Net Cash / Leverage $297M Net Cash $48M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning KYMR
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 129.6% (23rd %ile) 116.5% (8th %ile)
Put/Call OI Skew 0.42x (Call-Skewed) 0.71x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: KYMR (5) vs INBX (2)
Institutional Metric KYMR INBX Criterion Row Edge
Market Capitalization
Scale
$10.9B $1.3B Larger Scale KYMR
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+466.4% -100.0% Higher Growth KYMR
Operating Margin (TTM)
Profitability
-396.0% 0.0% Higher Margin INBX
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-27.3% -1773.6% Higher ROE KYMR
52-Week Range Position
Momentum
78% ($62–$143) 21% ($57–$155) Stronger Trend KYMR
Beta / 30D Volatility
Risk Regime
1.04β · 54% Vol 2.53β · 120% Vol Lower Realized Risk KYMR
Unified Institutional Score
Composite Signal
47.1 / 100 (HOLD) 51.4 / 100 (HOLD) Higher Composite INBX
Trailing 12M Revenue (USD)
Operating Scale
$102M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 103.3x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$289M ($297M Net Cash) -$132M ($48M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon KYMR +32.77 pp
KYMR: +19.21% · INBX: -13.56%
3M Horizon KYMR +20.84 pp
KYMR: +2.91% · INBX: -17.93%
6M Horizon KYMR +83.39 pp
KYMR: +56.78% · INBX: -26.61%
1Y Horizon KYMR +92.25 pp
KYMR: +96.31% · INBX: +4.06%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period KYMR Revenue INBX Revenue KYMR Op. Margin INBX Op. Margin Margin Leader
FY2019 $0M N/A -1438.5% N/A KYMR
FY2020 $30M N/A -136.1% N/A KYMR
FY2021 $70M N/A -138.0% N/A KYMR
FY2022 $50M N/A -344.4% N/A KYMR
FY2023 $80M $0M -210.6% -12178.9% KYMR
FY2024 $50M $0M -555.8% -165724.0% KYMR
FY2025 $40M $0M -891.1% -10386.5% KYMR

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
KYMR CONSOLIDATION
62d in phase · OBV NEUTRAL
Current IV 129.6%
IV Percentile 23rd %ile
Put/Call OI Skew 0.42x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact KYMR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
INBX BREAKDOWN
134d in phase · OBV DISTRIBUTION
Current IV 116.5%
IV Percentile 8th %ile
Put/Call OI Skew 0.71x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact INBX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
KYMR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $10.9B market capitalization and -396.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
INBX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.3B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ KYMR vs INBX Key Questions & Quantitative Answers

As of Nov 16, 2026, Kymera Therapeutics, Inc. (KYMR) is the stronger overall head-to-head candidate over Inhibrx Biosciences, Inc. (INBX) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). KYMR carries a Unified Composite Score of 47.1/100 (HOLD) at $124.91 (N/M Forward P/E, -396.0% operating margin), whereas INBX carries 51.4/100 (HOLD) at $77.65 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While INBX currently prints a higher short-term Unified Composite Score (51.4/100 HOLD vs. KYMR 47.1/100 HOLD), KYMR captures the overall institutional head-to-head verdict (5–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-396.0% vs. 0.0% operating margin) and revenue trajectory (+466.4% vs. -100.0% YoY). Technical & Structure Timing Caution: KYMR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.7); meanwhile INBX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

KYMR leads the Growth & Scale pillar: KYMR posts +466.4% YoY revenue growth and +0.0% YoY earnings growth on $102M TTM revenue (N/A gross margin, -396.0% operating margin), compared with INBX at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), KYMR cumulative revenue shifted +33.3% while INBX shifted N/A. In operating R&D and SG&A reinvestment, KYMR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for INBX.

KYMR screens cheaper on headline valuation multiples. KYMR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 103.3x EV/Revenue (unreported FCF margin), whereas INBX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against KYMR (-27.3% ROE) versus INBX (-1773.6% ROE) capital efficiency.

In options market volatility and institutional positioning, KYMR carries 129.6% implied volatility (23rd %ile, Compressed (<25th %ile)), a 0.42x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.04β · 54% Vol realized risk). By comparison, INBX carries 116.5% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.71x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.53β · 120% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.